We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Adaptable Lateral Flow Test Reader Being Promoted at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
A lateral flow test reader for either existing assays or for user-designed tests will be highlighted at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Abingdon Health (York, United Kingdom) will be highlighting its [U.S.] Food and Drug Administration registered and CE marked lateral flow reader, the ADxLR5, in Booth 3838 at the Philadelphia meeting.

The next generation ADxLR5 Lateral Flow Assay reader incorporates a 10.1-inch touch screen with graphical user interface and icon driven software. More...
The sample draw with interchangeable inserts allows for the reading of a wide range of devices and assays. Connectivity is via two USB ports, Ethernet connection, or WiFi.

The ADxLR5 reader complements Abingdon Health's Seralite – FLC (free light chain) rapid test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories with results available in about 10 minutes rather than days or weeks.

In addition, The ADxLR5 is fully customizable for user-designed fluorescence or colorimetric tests and is compatible with most formats of cassettes and test strips. The instrument includes touchscreen PC software to augment flexible test system development.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Abingdon Health

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
All-in-One Molecular System
AIO M160
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Diane E. MacDougall et al., FIND Lp(a) Machine Learning Model: Targeted Screening Enrichment of Elevated Lipoprotein(a) in Atherosclerotic Cardiovascular Disease, JACC: Advances (2026). DOI: 10.1016/j.jacadv.2026.103114

Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)

Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.